BTIG Reiterates Rating on SNSE $SNSE
Key Points
- BTIG now rates Sensei Biotherapeutics Inc ($SNSE) "buy" with a $55 target.
- BTIG's $55 price target implies 323.08% upside from Sensei Biotherapeutics Inc's ($SNSE) current $13 share price.
- The Street's average $SNSE price target is $51.67 (Strong Buy).
- $SNSE last traded around $13.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG reiterated its rating on Sensei Biotherapeutics Inc ($SNSE) to a "buy" rating in a recent research note and set a price target of $55, a 323.08% upside from the current price.
Sensei Biotherapeutics Inc Stock Price
Shares of Sensei Biotherapeutics Inc ($SNSE) traded around $13 on Saturday.
Sensei Biotherapeutics Inc Earnings
Analysts Set New Price Targets
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Get Sensei Biotherapeutics Inc alerts
New 13F filings, insider trades, and analyst moves on $SNSE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.